|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1400 AUD | +3.70% |
|
+3.70% | -6.67% |
Projected Income Statement: Amplia Therapeutics Limited
| Fiscal Period: March | 2023 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 10 |
| Change | - | - | - | - | - |
| EBITDA 1 | - | - | -8.297 | -11.5 | -3.5 |
| Change | - | - | - | -38.61% | 69.57% |
| EBIT 1 | - | - | -8.389 | -11.6 | -3.6 |
| Change | - | - | - | -38.28% | 68.97% |
| Interest Paid | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | -7.707 | -11.6 | -3.6 |
| Change | - | - | - | -50.51% | 68.97% |
| Net income 1 | -6.242 | -6.572 | -7.707 | -11.6 | -3.6 |
| Change | - | - | -17.27% | -50.51% | 68.97% |
| Announcement Date | 5/30/23 | 5/30/25 | 5/29/26 | - | - |
1AUD in Million
Estimates
Forecast Balance Sheet: Amplia Therapeutics Limited
| Fiscal Period: March | 2023 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | -27.9 | -15.5 | -21.5 |
| Change | - | - | - | 44.35% | -38.71% |
| Announcement Date | 5/30/23 | 5/30/25 | 5/29/26 | - | - |
1AUD in Million
Estimates
Cash Flow Forecast: Amplia Therapeutics Limited
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| CAPEX 1 | 0.005347 | 0.0144 | 0.0176 | 0.002226 | 0.002072 | 0.0333 |
| Change | - | 169.35% | 22.42% | -87.37% | -6.92% | 1,507.19% |
| Free Cash Flow (FCF) 1 | -2.103 | -3.074 | -2.986 | -3.59 | -4.772 | -6.482 |
| Change | - | -46.21% | 2.87% | -20.24% | -32.92% | -35.84% |
| Announcement Date | 6/29/21 | 5/29/22 | 5/30/23 | 5/30/24 | 5/30/25 | 5/29/26 |
1AUD in Million
Estimates
Forecast Financial Ratios: Amplia Therapeutics Limited
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | - | - | - | - | - | - | - | -35% |
| EBIT Margin (%) | - | - | - | - | - | - | - | -36% |
| EBT Margin (%) | - | - | - | - | - | - | - | -36% |
| Net margin (%) | - | - | - | - | - | - | - | -36% |
| FCF margin (%) | - | - | - | - | - | - | - | - |
| FCF / Net Income (%) | - | - | - | - | - | - | - | - |
Profitability | ||||||||
| ROA | -14.63% | -12.88% | -18.2% | -17.04% | -22.47% | -16.29% | - | - |
| ROE | -24.08% | -22.64% | -33.13% | -33.05% | -40.51% | -25.48% | - | - |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - | - | - | - |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | - | - | - | - | - | - | - | - |
| CAPEX / EBITDA (%) | - | - | - | - | - | - | - | - |
| CAPEX / FCF (%) | - | - | - | - | - | - | - | - |
Items per share | ||||||||
| Cash flow per share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Dividend per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Book Value Per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| EPS 1 | - | - | -0.0322 | - | -0.0214 | -0.0164 | -0.023 | -0.006 |
| Change | - | - | - | - | - | 23.36% | -40.24% | 73.91% |
| Nbr of stocks (in thousands) | - | - | 194,006 | - | 387,953 | 513,072 | 513,312 | 513,312 |
| Announcement Date | - | - | 5/30/23 | - | 5/30/25 | 5/29/26 | - | - |
1AUD
Estimates
| 2027 * | 2028 * | |
|---|---|---|
| P/E | -5.87x | -22.5x |
| PBR | - | - |
| EV / Sales | - | 4.78x |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1350AUD
Average target price
0.4200AUD
Spread / Average Target
+211.11%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ATX Stock
- Financials Amplia Therapeutics Limited
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
